Bioinformatics analysis and experimental validation of C6orf120 as a potential prognostic marker and therapeutic target for liver hepatocellular carcinoma

Authors

  • Yingying Lin Center of Integrative Medicine, Peking University Ditan Teaching Hospital, Beijing, China
  • Xin Wang Center of Integrative Medicine, Peking University Ditan Teaching Hospital, Beijing, China
  • Yanyan Li Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China
  • Xinyu Cui Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China
  • Na Zhu Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China
  • Xin Li Center of Integrative Medicine, Peking University Ditan Teaching Hospital, Beijing, China; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China

DOI:

https://doi.org/10.17305/bb.2024.11246

Keywords:

C6orf120, liver hepatocellular carcinoma, prognosis, immune, angiogenesis , tumor microenvironment

Abstract

The C6orf120 gene is a novel gene whose function has not been fully defined. Previous studies have associated it with various liver pathologies, but its specific role in hepatocellular carcinoma (LIHC) remains unclear. This study aimed to investigate the diagnostic and prognostic value of C6orf120 in LIHC, as well as its potential biological functions. In this preliminary research, we utilized data from various databases and bioinformatics tools, including TCGA, GEO, TIMER2, HPA, GEPIA, Linkeomics, Metascape, CIBERSORT, TargetScan, DIANA-microT, RNAinter, and ENCORI, to analyze the expression patterns and mechanisms of C6orf120 in LIHC. Our bioinformatics analysis revealed that C6orf120 is upregulated in LIHC and may serve as a diagnostic and prognostic biomarker. The aberrant expression of C6orf120 in LIHC was further supported by clinical samples and cell lines. In vitro experiments demonstrated that the knockdown of C6orf120 in HepG2 cells significantly reduced migration capacity without affecting proliferation. Additionally, the downregulation of C6orf120 in LIHC cells appeared to inhibit endothelial cell migration and angiogenesis, which are critical in tumorigenesis and development. In conclusion, our findings suggest that C6orf120 could serve as a novel diagnostic and prognostic biomarker for LIHC and is expected to be a prognostic marker and a potential therapeutic target in the clinical management of LIHC.

Citations

Downloads

Download data is not yet available.
Bioinformatics analysis and experimental validation of C6orf120 as a potential prognostic marker and therapeutic target for liver hepatocellular carcinoma

Downloads

Additional Files

Published

10-10-2024

How to Cite

1.
Bioinformatics analysis and experimental validation of C6orf120 as a potential prognostic marker and therapeutic target for liver hepatocellular carcinoma. Biomol Biomed [Internet]. 2024 Oct. 10 [cited 2024 Dec. 11];. Available from: https://bjbms.org/ojs/index.php/bjbms/article/view/11246